Related Experiment Video
Updated: Dec 14, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
COVID-19-associated coagulopathy
Massimo Franchini1,2, Giuseppe Marano1, Mario Cruciani1,3
1Italian National Blood Centre, Rome, Italy.
Insights
Coronavirus disease 2019 (COVID-19) causes a prothrombotic state due to links between inflammation and clotting. Monitoring coagulation in severe COVID-19 patients is crucial for managing thrombotic risk and guiding treatment.
Area of Science:
- Hematology
- Infectious Diseases
- Pathophysiology
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a systemic illness associated with a prothrombotic state.
- The precise molecular mechanisms linking inflammation and hemostasis in COVID-19 coagulopathy remain under investigation.
Purpose of the Study:
- To review the current understanding of COVID-19-associated coagulopathy.
- To summarize its pathogenesis, epidemiology, clinical and laboratory features, and management strategies.
Main Methods:
- This is a review article.
- It synthesizes existing research on COVID-19 and coagulation.
Main Results:
- COVID-19 induces a hypercoagulable state, increasing thrombotic risk in patients.
- Laboratory monitoring is essential for identifying at-risk individuals and optimizing thromboprophylaxis.
Conclusions:
- Understanding COVID-19 coagulopathy is vital for clinical management.
- Further research into the pathogenesis and effective treatment of this complication is warranted.
Abstract:
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized as a systemic disorder inducing a prothrombotic state. The molecular mechanisms underlying the hypercoagulable state seen in patients with COVID-19 is still incompletely understood, although it presumably involves the close link between inflammatory and hemostatic systems. The laboratory coagulation monitoring of severely ill COVID-19 patients is mandatory to identify those patients at increased thrombotic risk and to modulate thromboprophylaxis accordingly. In this review, we summarize the current understanding on the pathogenesis, epidemiology, clinical and laboratory features and management of coagulopathy associated with COVID-19.
Related Concept Videos
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

